

## Special Issue

# Understanding Hodgkin's Lymphoma: The Role of Tumour Cells and Immune Microenvironment

### Message from the Guest Editor

The dynamic interaction of neoplastic cells with the surrounding microenvironment, comprised of stromal cells and an extracellular matrix, is essential. This process promises to support the heterogeneity of the tumour compartment, and to assist in overcoming inadequate responses to therapy and increased multidrug resistance. In this context, Hodgkin's lymphoma (HL), one of the most enigmatic cancers in which few neoplastic cells are within an abundant but ineffective immune ecosystem, represents a paradigmatic tumour for study. For this Special Issue, we welcome articles or reviews on discoveries or new concepts to clarify the interaction between cancer, non-neoplastic cells and stroma, emphasise how this could be targeted to reduce tumour progression and loss of response to therapy, and highlight the prospects for improvement in patient management. I look forward to receiving your contributions.

### Guest Editor

Prof. Dr. Massimo Mascolo

Pathology Unit, Department of Advanced Biomedical Sciences,  
University Federico II of Naples, 80131 Naples, Italy

### Deadline for manuscript submissions

closed (29 November 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/149934](https://mdpi.com/si/149934)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)